US Hormone Replacement Therapy Market

The U.S. hormone replacement therapy market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of XX% during 2023–2031. The growth of the market is attributed to the increasing number of incidences due to hormonal imbalance disorders and rising neonates suffering from these diseases.

Hormone replacement therapy includes a range of diagnosis and treatment of the health conditions for women having low hormone levels. Women, having this disorder, usually takes progestin and often estrogen to combat the symptoms aroused by low hormone levels. As per a study released by the University of Wisconsin Hospitals and Clinics Authority, the chances of hypogonadism rises with age and over 11.0% of men with the age of 50 years and 18.0% of men with the age of 60 years are likely to suffer from hypogonadism in the U.S. In the country, it is also reported that most of these cases remains undertreated and underdiagnosed. American Thyroid Association advised that over 11.0% of the U.S. population is estimated to experience thyroid disorder in their life span and approximately 19.0 million U.S. citizens have some form of thyroid disease.

Get Free Sample Report

One in every 4000 neonates are likely to experience congenital hypothyroidism and left unattended, which lead to result in the severe consequence such as mental retardation, according to the Centers for Disease Control and Prevention (CDC). The main players are focusing in the development of innovative products with various formulation to increase acceptance and compliance among patients, which is further expected to boost market growth.

U.S. Hormone Replacement Therapy Market Trends, Drivers, Restraints, and Opportunities

• Increasing incidences of different hormonal imbalance disorders and rising geriatric population experiencing these diseases are expected to fuel market growth.

• Increasing awareness about such diseases and wide adoption of the therapy among patients are key factors boosting the growth of the market.

• High incidences of congenital disorder in newborns and increasing incidences of vasomotor symptom and vaginal atrophy are expected to drive the market.

• Adverse reactions and risk of cancer in women due to drugs found in estrogen therapy is expected to restrain the market growth.

• High cost of treatment of hormone replacement therapy is a key challenge that can hinder the market revenue.

Scope of U.S. Hormone Replacement Therapy Market Report

The report on the U.S. hormone replacement therapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

U.S. Hormone Replacement Therapy Market Segment Insights

Estrogen & progesterone replacement therapy segment is expected to grow at a rapid pace

Based on products, the U.S. hormone replacement therapy market is divided into estrogen & progesterone replacement therapy, replacement therapy, thyroid hormone replacement therapy, testosterone replacement, therapy, parathyroid hormone, and human growth hormone. The estrogen & progesterone replacement therapy segment is expected to grow at a rapid pace in the coming years owing to introduction of innovative products and technology. However, the parathyroid hormone segment is anticipated to expand at a substantial growth rate during the forecast period due to the approval of U.S. Food and Drug Administration for the use of recombinant human parathyroid hormone, which is for the treatment of adults with chronic diseases.

Get Free Sample Report

Oral segment is projected to account for a key market share

On the basis of route of administration, the market is segregated into oral, parenteral, transdermal, and others. The oral segment is projected to account for a key share of the market during the forecast period owing to introduction of oral testosterone products. Meanwhile, the parenteral segment is anticipated to expand at a considerable CAGR during the forecast period due to the launch of long-acting growth hormones and pen-based versions to contribute to accurate dosing and reduced adverse effects from chronic diseases.

Menopause segment is expected to expand at a robust growth rate

Based on disease types, the U.S. hormone replacement therapy market is divided into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, and hypoparathyroidism. The menopause segment is expected to expand at a robust growth rate during the forecast period owing to rise in the number of menopausal women and rise in the number of vasomotor symptoms incidences. On the other hand, the hypoparathyroidism segment is anticipated to constitute a key market share during the forecast period due to increase in the number of innovative products and novel treatments.

Segments

The U.S. hormone replacement therapy market has been segmented on the basis of

Products

• Estrogen & Progesterone Replacement Therapy
• Human Growth Hormone (HGH) Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Replacement Therapy
• Parathyroid Hormone

Routes of Administration

• Oral
• Parenteral
• Transdermal
• Others

Disease Types

• Menopause
• Hypothyroidism
• Male Hypogonadism
• Growth Hormone Deficiency
• Hypoparathyroidism

Country

• The United States

Key Players

• Abbott
• Pfizer, Inc.
• AbbVie Inc
• Mylan N.V.
• Merck & Co. Inc.
• Novo Nordisk A/S
• Bayer Cropscience Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche AG

Competitive Landscape

Key players competing in the U.S. hormone replacement therapy market are Abbott; Pfizer, Inc.; AbbVie Inc; Mylan N.V.; Merck & Co. Inc.; Novo Nordisk A/S; Bayer Cropscience Ltd.; Eli Lilly and co.; F. Hoffmann La Roche AG. These main players are focusing in the development of innovative products with various formulation to increase patient acceptance and compliance, which is further expected to lead the market growth. Novo Nordisk A/S announced that it got the U.S. FDA acceptance for its products’ Biologics License Application for Sogroya in August 2020.